Researchers reviewed autopsy data from 22 different studies, sharing their findings in Cardiovascular Pathology.

A history of heart failure was also associated with longer lengths of stay and an increased risk of mechanical ventilation.

Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes. 

The increasingly popular ketogenic diet could be a valuable tool in the fight against heart failure, according to a new study published in Nature Metabolism.

The research, published in Circulation, focused on the combination of pharmacologic therapy and the temporary use of a left ventricular assist device.

In-hospital mortality, myocardial injury and acute kidney injury were all more common when patients with a history of heart failure tested positive for COVID-19. 

Catheter ablation was consistently linked to more substantial LVEF improvements than pharmacological therapy.

The analysis included data from nearly 800 patients with a history of chronic heart failure.